Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the company’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $475.27, for a total transaction of $1,901,080.00. Following the completion of the transaction, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $61,785.10. The trade was a 96.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

United Therapeutics Trading Up 1.1%

NASDAQ:UTHR traded up $5.21 during midday trading on Friday, hitting $489.31. 303,005 shares of the company were exchanged, compared to its average volume of 582,184. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $492.62. The company has a market capitalization of $21.07 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 4.78 and a beta of 0.86. The company has a fifty day simple moving average of $451.78 and a 200 day simple moving average of $366.63.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter last year, the company posted $6.39 earnings per share. The business’s quarterly revenue was up 6.8% compared to the same quarter last year. As a group, equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently bought and sold shares of UTHR. Wilmington Savings Fund Society FSB lifted its position in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the period. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics during the 2nd quarter worth approximately $29,000. Abich Financial Wealth Management LLC purchased a new position in shares of United Therapeutics during the 3rd quarter worth approximately $44,000. SVB Wealth LLC acquired a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $32,000. Finally, WealthCollab LLC boosted its stake in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of several research analyst reports. Royal Bank Of Canada lifted their price target on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research report on Thursday, October 30th. Bank of America raised their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Morgan Stanley set a $447.00 price target on shares of United Therapeutics in a research report on Wednesday, October 29th. UBS Group raised their price objective on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $505.00.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.